Opyt dlitel'noy terapii patsientov s pishchevodom Barretta


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A 5-year prospective randomized trial on the efficacy of treatment of Barrett's esophagus in elderly patients was carried out. 31 patients (mean age 66,8 years) and 30 patients (mean age 66,2 years) were assigned to group A and B, respectively. Patients of group A were treated with omeprazole (20 mg twice a day) and Urosan (10mg/kg/day), while patients of group B received omeprazole (20 mg twice a day) for 5 years. At the end of the follow-up period metaplasia of the lower third of esophagus was not found in 32,3% patients of group A and 6,7% of patients of group B (р=0,03). After 5 years of treatment, esophagitis was diagnosed in 12,9% patients of group A and 53,3% patients of group B (р=0,002). In conclusion, combination of omeprazole and ursodeoxycholic acid (Urosan) as a means of treatment for Barrett's esophagus in elderly patients was superior to omeprazole monotherapy.

Full Text

Restricted Access

References

  1. Цуканов В.В., Хоменко О.В., Ржавичева О.С., Буторин Н.Н., Штыгашева О.В., Маады А.С., Бичурина Т.Б., Амельчугова О.С. Распространенность H. pylori и ГЭРБ у монголоидов и европеоидов Восточной Сибири. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2009; 3:38-41.
  2. Буторин Н.Н., Бичурина Т.Б., Цуканов В.В., Каспаров Э.В., Куклин Д.В., Тимошенко В.О., Штыгашева О.В., Маады А.С., Васютин А.В. Распространенность и клинические аспекты пищевода Барретта у населения Восточной Сибири. Терапевт. архив. 2013;1:62-5.
  3. Rajendra S., Sharma P. Barrett's Esophagus. Curr. Treat. Options. Gastroenterol. 2014;12(2):169-82.
  4. Maradey-Romero C., Fass R. New and future drug development for gastroesophageal reflux disease. J. Neurogastroenterol. Motil. 2014;20(1):6-16.
  5. Bennett C., Vakil N., Bergman J. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143(2):336-46.
  6. Khalaf N., Nguyen T., Ramsey D., El-Serag H.B. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2014;12(11):1832-39.
  7. Vakil N., van Zanden S.V., Kahrilas P., Dent J., Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006; 101(8):1900-20.
  8. Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P., Johnson F., Hongo M., Richter J.E., Spechler S.J., Tytgat G.N., Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:2:172-80.
  9. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20(5):40-7.
  10. Ушаева Л.А., Балалыкин Д.А. Хромоэндоскопия в диагностике злокачественных новообразований. Эндоскопическая хирургия. 2008;5:32-3.
  11. Sharma P., McQuaid K., Dent J., Fennerty M.B., Sampliner R., Spechler S., Cameron A., Corley D., Falk G., Goldblum J., Hunter J., Jankowski J., Lundell L., Reid B., Shaheen N.J., Sonnenberg A., Wang K., Weinstein W.; AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310-30.
  12. Агеева Е.С., Штыгашева О.В., Цуканов В.В., Рязанцева Н.В. Иммунологические особенности течения гастродуоденальной патологии у жителей Хакасии. Иммунология. 2009;3:162-65.
  13. Цуканов В.В., Амельчугова О.С., Буторин Н.Н., Третьякова О.В., Васютин А.В. Современные аспекты эрадикации Helicobacter pylori. Терапевт. архив. 2013;2:73-5.
  14. Cheng P., Li J.S., Gong J., Zhang L.F., Chen R.Z. Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma. World J. Gastroenterol. 2011;17(25):3060-065.
  15. Ojima E., Fujimura T., Oyama K. Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid. Clin. Exp. Med. 2014;18. [Epub ahead of print].
  16. Matsuzaki J.,Suzuki H., Tsugawa H., Watanabe M., Hossain S., Arai E., Saito Y., Sekine S., Akaike T., Kanai Y., Mukaisho K., Auwerx J., Hibi T. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145(6):1300-11.
  17. Peng S., Huo X., Rezaei D., Zhang Q., Zhang X., Yu C., Asanuma K., Cheng E., Pham T.H., Wang D.H., Chen M., Souza R.F., Spechler S.J. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am. J. Physiol. Gastrointest. 2014;307(2):G129-G139.
  18. Haidry R.J., Butt M.A., Dunn J.M., Gupta A., Lipman G., Smart H.L., Bhandari P., Smith L., Willert R., Fullarton G., Di Pietro M., Gordon C., Penman I., Barr H., Patel P., Kapoor N., Hoare J., Narayanasamy R., Ang Y., Veitch A., Ragunath K., Novelli M., Lovat L.B.; on behalf of the UK RFA Registry. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut. 2014;24. [Epub ahead of print].
  19. Singh S., Garg S.K., Singh P.P., Iyer P.G., El-Serag H.B. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8): 1229-37.
  20. Peura D.A., Wilcox C.M. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus. Postgrad Med. 2014; 126(1):87-96.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies